BG111544A - Субституирани бензамидни производни като in vitro mao-b инхибитори - Google Patents

Субституирани бензамидни производни като in vitro mao-b инхибитори

Info

Publication number
BG111544A
BG111544A BG111544A BG11154413A BG111544A BG 111544 A BG111544 A BG 111544A BG 111544 A BG111544 A BG 111544A BG 11154413 A BG11154413 A BG 11154413A BG 111544 A BG111544 A BG 111544A
Authority
BG
Bulgaria
Prior art keywords
alkyl
substituted
hydrogen atoms
halogen atom
inhibitors
Prior art date
Application number
BG111544A
Other languages
English (en)
Inventor
Николай Цветков
Original Assignee
Николай Цветков
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Николай Цветков filed Critical Николай Цветков
Priority to BG111544A priority Critical patent/BG111544A/bg
Priority to EP14831149.1A priority patent/EP2991986B1/en
Priority to PCT/BG2014/000027 priority patent/WO2015013777A2/en
Priority to US14/904,893 priority patent/US9738640B2/en
Publication of BG111544A publication Critical patent/BG111544A/bg

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Изобретението се отнася до субституирани бензамидни производни с обща формула I където А1 и А2 са -N или -СН, така че ако А1 е -N, А2 е -СН и ако А2 е -N, то А1 е -СН; R е водород, -(С1-С3)-алкил с права или разклонена верига, -(С1-С3)-алкил, където един, два или три водородни атома могат да бъдат субституирани с халогенен атом или хидроксилна група, -(С1-С3)-O-(С1-С3), -(С1-С3)-O-(С1-С3), където един, два или три водородни атома могат да бъдат заместени с халогенен атом или е група с обща формула където R3 и R4 са едновременно или независимо един от друг халоген, хидрокси, -(С1-С3)-алкил, -(С1-С3)-алкил, в молекулата на който един, два или три водородни атома могат да бъдат субституирани с халогенен атом или хидроксилна група, -О-(С1-С3)-алкил, -О-(С1-С3)-алкил, в молекулата на който един, два или три водородни атома могат да бъдат субституирани с халогенен атом, -О-(С1-С3)-О-(С1-С3), -О-(С1-С3)-О-(С1-С3), където един, два или три водородни атома могат да бъдат субституирани с халогенен атом; R1 и R2 едновременно или независимо един от друг са халоген, хидрокси, -(С1-С3)-алкил и -(С1-С3)-алкил, където един, два или три водородни атома могат да бъдат субституирани с халогенен атом или хидроксилна група, -О-(С1-С3)-алкил, -О-(С1-С3)-алкил, където един, два или три водородни атома могат да бъдат субституирани с халогенен атом, -О-(С1-С3)-О-(С1-С3), -О-(С1-С3)-О-(С1-С3), където един, два или три водородни атома могат да бъдат субституирани с халогенен атом, както и техни фармацевтично приемливи соли, изомери или смеси от тях. Съединенията са приложими като in vitro селективни МАО-В инхибитори за превенция и лечение на акутни и хронични неврологични, когнитивни и невродегенеративни заболявания и по-специално за превенция и лечение на Паркинсонова болест и Алцхаймер. 4 претенции, 1 фигура
BG111544A 2013-07-29 2013-07-29 Субституирани бензамидни производни като in vitro mao-b инхибитори BG111544A (bg)

Priority Applications (4)

Application Number Priority Date Filing Date Title
BG111544A BG111544A (bg) 2013-07-29 2013-07-29 Субституирани бензамидни производни като in vitro mao-b инхибитори
EP14831149.1A EP2991986B1 (en) 2013-07-29 2014-07-11 Substituted benzamide derivatives as mao-b inhibitors
PCT/BG2014/000027 WO2015013777A2 (en) 2013-07-29 2014-07-11 Substituted benzamide derivatives as in vitro mao-b inhibitors
US14/904,893 US9738640B2 (en) 2013-07-29 2014-07-11 Substituted benzamide derivatives as in vitro MAO-B inhibitors

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
BG111544A BG111544A (bg) 2013-07-29 2013-07-29 Субституирани бензамидни производни като in vitro mao-b инхибитори

Publications (1)

Publication Number Publication Date
BG111544A true BG111544A (bg) 2015-01-30

Family

ID=52432494

Family Applications (1)

Application Number Title Priority Date Filing Date
BG111544A BG111544A (bg) 2013-07-29 2013-07-29 Субституирани бензамидни производни като in vitro mao-b инхибитори

Country Status (4)

Country Link
US (1) US9738640B2 (bg)
EP (1) EP2991986B1 (bg)
BG (1) BG111544A (bg)
WO (1) WO2015013777A2 (bg)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024124464A1 (zh) * 2022-12-15 2024-06-20 武汉睿健医药科技有限公司 一种诱导间质细胞向上皮细胞转化及重编程的诱导剂
WO2024124463A1 (zh) * 2022-12-15 2024-06-20 武汉睿健医药科技有限公司 一种吡咯并吡啶衍生物及其药物组合物与应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA979961B (en) 1996-11-15 1999-05-05 Lilly Co Eli 5-HT1F agonists
US20050075364A1 (en) 2003-07-01 2005-04-07 Kap-Sun Yeung Indole, azaindole and related heterocyclic N-substituted piperazine derivatives
JP4898683B2 (ja) 2004-09-03 2012-03-21 ユーハン・コーポレイション ピロロ［２，３−ｃ］ピリジン誘導体及びその製造方法
WO2009061730A2 (en) 2007-11-05 2009-05-14 Array Biopharma Inc. 4-heteroaryl-substituted phenoxyphenylacetic acid

Also Published As

Publication number Publication date
EP2991986B1 (en) 2017-03-08
US9738640B2 (en) 2017-08-22
WO2015013777A2 (en) 2015-02-05
WO2015013777A9 (en) 2015-11-19
WO2015013777A3 (en) 2016-01-14
EP2991986A2 (en) 2016-03-09
US20160152611A1 (en) 2016-06-02

Similar Documents

Publication Publication Date Title
PH12015502502A1 (en) Heteroaromatic compounds and their use as dopamine d1 ligands
PH12014501719A1 (en) Pyridone derivatives
BR112015028501A2 (pt) derivados de bipirazol como inibidores de jak
PH12016501204A1 (en) Syk inhibitors
MA33838B1 (fr) Forme amorphe et cristalline de l'hémitartrate de genz 112638 au titre d'inhibiteur de la glucosylcéramide synthétase
PH12019500480A1 (en) Pyridine compound
AU2012258977A8 (en) Inhibitors of LRRK2 kinase activity
IN2014DN05772A (bg)
BR112015009395A2 (pt) processo para preparação de derivados do ácido biliar
MA37866A1 (fr) Dérivés de type aza-indazole ou diaza-indazole pour le traitement de la douleur
BR112015009649A2 (pt) composto de triazolo
GEP20166483B (en) Phenyl-3-aza-bicyclo[3.1.0] hex-3-yl-methanones and the use thereof as medicament
TN2015000005A1 (en) Azaindole derivatives which act as pi3k inhibitors
CA2920410C (en) Thienopiperidine derivative and use thereof
IN2015MN00002A (bg)
CR20130693A (es) Composición farmacéutica ortalmológica tópica que contiene regorafenib
DOP2015000214A (es) Nuevos compuestos inhibidores de la fosfodiesterasa del tipo 10a
MX2015008733A (es) Derivados de 1,2,3-triazol-4-amina para el tratamiento de enfermedades y transtornos relacionados con receptores sigma.
BG111544A (bg) Субституирани бензамидни производни като in vitro mao-b инхибитори
BG111378A (bg) Субституирани индазолови производни като in-vitro mao-b инхибитори
BR112012029815A2 (pt) derivados de flufenoxina pra o tratamento e prevenção de patologias amiloides
BR112015007507A2 (pt) compostos de [3-heteroaril-2-trifluorometil-propil]-piperidin-1-ila ou –morfolin-4-ila como antagonistas trpa1 para o tratamento de doenças respiratórias
TR201901937T4 (tr) 8-metil-1-fenil-imidazol[1,5-a]pirazin bileşikleri.
PL398731A3 (pl) Inhibitory cholinoesteraz o strukturze hybrydowej
IN2012DE00262A (bg)